Abstract:Ferroptosis is a recently recognized form of regulated cell death. It is characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. It can be induced by experimental compounds (e.g., erastin, Ras-selective lethal small molecule 3, and buthionine sulfoximine) or clinical drugs (e.g., sulfasalazine, sorafenib, and artesunate) in cancer cells and certain normal cells (e.g., kidney tubule cells, neurons, fibroblasts, and T cells). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism and can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and desferrioxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin, liproxstatin, and zileuton). Glutathione peroxidase 4, heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 (especially acetylation-defective mutant p53) act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. In this review, we summarize the regulation mechanisms and signaling pathways of ferroptosis and discuss the role of ferroptosis in disease.

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

Ferroptosis: Death by lipid peroxidation

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy

Ferroptosis: process and function

Ferroptosis and Its Potential Role in Human Diseases

Ferroptosis: Regulatory mechanisms and potential targets for bone metabolism: A review

Ferroptosis: molecular mechanisms and health implications

Ferroptosis in Cancer Cell Biology

Ferroptosis as a novel form of regulated cell death: Implications in the pathogenesis, oncometabolism and treatment of human cancer

Ferroptosis, a new form of cell death, and its relationships with tumourous diseases

Ferroptosis: A New Strategy for Cancer Therapy.

The Chemistry and Biology of Ferroptosis

Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs.

Ferroptosis: principles and significance in health and disease

Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy

Activation of lysosomal iron triggers ferroptosis in cancer

Ferroptosis, a New Form of Cell Death: Opportunities and Challenges in Cancer

Ferroptosis and its potential as a therapeutic target

Revealing the Ferroptotic Phenotype of Medulloblastoma